Vanda Pharmaceuticals Inc.
VNDA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $216M | $199M | +8.7% |
| Operating income | −$151M | −$40.7M | −272% |
| Net income | −$220M | −$18.9M | −1,067% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 29, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $69.8M | $56.3M | +24.0% |
| Operating income | −$23.5M | −$31.3M | +24.9% |
| Net income | −$22.6M | −$22.6M | +0.0% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Vanda Pharmaceuticals's revenue in FY2025?
- $216M in FY2025 (Fiscal year ended Dec 31, 2025), +8.7% vs $199M a year earlier, per its 10-K filed Feb 2026.
- Was Vanda Pharmaceuticals profitable in FY2025?
- No: net income was −$220M and operating income −$151M in FY2025.
- What was Vanda Pharmaceuticals's revenue in Q3 2026?
- $69.8M (+24.0% vs a year earlier), per its Form 10-Q filed Oct 29, 2026.